Clinical Trials Browser

Phase 1/2 × Interventional × veliparib × Clear all

NCT01386385 2026-05-26

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 1/2 Active not recruiting

53 enrolled 21 charts

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

NCT01012817 2026-04-29

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Phase 1/2 Active not recruiting

88 enrolled 23 charts

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT01489865 2025-11-06

ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer

Phase 1/2 Completed

64 enrolled 20 charts

Gastrointestinal

Pancreatic Neoplasms

NCT01711541 2023-06-07

Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer

Phase 1/2 Completed

24 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms

NCT01642251 2023-05-06

Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

Phase 1/2 Completed

156 enrolled 13 charts

EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Neuroendocrine, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT02412371 2020-07-22

A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Terminated

48 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT02289690 2020-05-14

Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer

Phase 1/2 Completed

221 enrolled 37 charts

Small Cell Lung Carcinoma

NCT01326702 2019-12-16

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

Phase 1/2 Completed

43 enrolled 18 charts

DermatologicLymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT01514201 2019-08-13

Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas

Phase 1/2 Completed

66 enrolled 24 charts

Astrocytoma, Glioblastoma, Gliosarcoma

NCT01026493 2017-07-02

Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma

Phase 1/2 Completed

257 enrolled 16 charts

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT01472783 2016-11-16

Veli-BRCA

Phase 1/2 Completed

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Recurrence

NCT01690598 2015-06-10

Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status

Phase 1/2 Completed

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms